Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A, Ramlau R, Falcón González A, Chaudhry A, Todenhöfer T, Tahbaz R, Fontana E, Giannatempo P, Deville JL, Pouessel D, Yoon S, Powles T, Bernat M, Häckl M, Marszewska M, McKernan P, Saulay M, Scaleia F, Engelhardt M, Loriot Y, Siefker-Radtke A, De Santis M.
Necchi A, et al. Among authors: bernat m.
JNCI Cancer Spectr. 2024 Apr 16:pkae030. doi: 10.1093/jncics/pkae030. Online ahead of print.
JNCI Cancer Spectr. 2024.
PMID: 38627238